CompanyOPTHNasdaqVancouver, A1

Optimi Health Corp.

Optimi Health manufactures GMP-grade MDMA and psilocybin drug products for mental health therapies.

SEC EDGAR ClinicalTrials.gov sedarplus.ca

6-KSep 29Latest SEC filing

Sep 23Latest story

September 2026

Optimi Health finishes psilocybin batch for Canadian MDD trial and Australian TRD supply

Sep 23Regulatory decisionOptimi Health Corp.psilocybin

Optimi Health names Michael Blough to lead clinical development for psychedelic trials

Sep 22Clinical readoutOptimi Health Corp.

August 2026

Optimi Health CEO buys 3,800 shares via affiliated company

Aug 7PeopleOptimi Health Corp.

July 2026

Optimi Health CEO Dane Stevens buys 18,700 shares in mid-July trades

Jul 20PeopleOptimi Health Corp.